MA45797A - Mutant de mg53, son procédé de préparation et ses utilisations - Google Patents

Mutant de mg53, son procédé de préparation et ses utilisations

Info

Publication number
MA45797A
MA45797A MA045797A MA45797A MA45797A MA 45797 A MA45797 A MA 45797A MA 045797 A MA045797 A MA 045797A MA 45797 A MA45797 A MA 45797A MA 45797 A MA45797 A MA 45797A
Authority
MA
Morocco
Prior art keywords
mutant
preparation process
preparation
Prior art date
Application number
MA045797A
Other languages
English (en)
Inventor
Sile Guo
Fengxiang Lu
Rui-Ping Xiao
Yan Zhang
Original Assignee
Hope Medicine Nanjing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201610847346.4A external-priority patent/CN107868125A/zh
Application filed by Hope Medicine Nanjing Co Ltd filed Critical Hope Medicine Nanjing Co Ltd
Publication of MA45797A publication Critical patent/MA45797A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
MA045797A 2016-08-01 2017-07-20 Mutant de mg53, son procédé de préparation et ses utilisations MA45797A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610621989 2016-08-01
CN201610847346.4A CN107868125A (zh) 2016-09-23 2016-09-23 Mg53突变体及其制备方法和用途
CN201710560975 2017-07-11

Publications (1)

Publication Number Publication Date
MA45797A true MA45797A (fr) 2021-04-21

Family

ID=61073266

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045797A MA45797A (fr) 2016-08-01 2017-07-20 Mutant de mg53, son procédé de préparation et ses utilisations

Country Status (10)

Country Link
US (1) US11306296B2 (fr)
EP (1) EP3492491A4 (fr)
JP (1) JP7144402B2 (fr)
KR (1) KR102483242B1 (fr)
CN (1) CN108473546B (fr)
CA (1) CA3031856C (fr)
MA (1) MA45797A (fr)
SG (1) SG11201900459RA (fr)
TW (1) TWI781948B (fr)
WO (1) WO2018024110A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108478800A (zh) * 2018-04-02 2018-09-04 慎东 含mg53/其突变体的组合物在制备炎症性肠病药物的应用
AU2019392087A1 (en) * 2018-12-07 2021-06-24 Ohio State Innovation Foundation Composition for and method of facilitating corneal tissue repair
EP3982999B1 (fr) * 2019-06-17 2026-01-28 Trim-Edicine, Inc. Composition et méthode de traitement d'une lésion tissulaire hépatique
CN115379823A (zh) * 2020-01-23 2022-11-22 俄亥俄州立创新基金会 药妆组合物
US20250381305A1 (en) * 2022-06-28 2025-12-18 Sineugene Therapeutics Co., Ltd. Method for treating a parkinson's disease
CN119452081A (zh) * 2022-06-28 2025-02-14 神济昌华(北京)生物科技有限公司 用于治疗神经系统疾病的aav基因疗法
WO2024002062A1 (fr) * 2022-06-28 2024-01-04 Sineugene Therapeutics Co., Ltd. Protéine tronquée et son utilisation
EP4720101A1 (fr) * 2023-05-26 2026-04-08 Ohio State Innovation Foundation Polypeptides mg53 modifiés et leurs procédés d'utilisation
WO2024249316A1 (fr) * 2023-05-26 2024-12-05 Ohio State Innovation Foundation Polypeptides trim72/mg53 recombinants et leurs procédés d'utilisation
WO2025030108A2 (fr) * 2023-08-03 2025-02-06 Ohio State Innovation Foundation Compositions de mitsugumine-53 humaine recombinante et leurs procédés d'utilisation
WO2025214465A1 (fr) * 2024-04-12 2025-10-16 Hope Medicine (Wuxi) Co., Ltd. Variants de mg53, protéines de fusion les comportant et leurs utilisations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703219B1 (en) 1993-02-26 2004-03-09 Immtech International Inc. Mutant protein and methods and materials for making and using it
WO2005035723A2 (fr) 2003-10-07 2005-04-21 United Therapeutics Corporation Mutant de tyrosinase et procedes d'utilisation correspondants
ES2479668T3 (es) 2006-07-11 2014-07-24 University Of Medicine And Dentistry Of New Jersey Proteínas de reparación de la membrana celular, ácidos nucleicos que las codifican y métodos de uso asociados
US9139630B2 (en) 2006-07-11 2015-09-22 Rutgers, The State University Of New Jersey Compositions and methods for preparing recombinant MG53 and methods for optimizing same
WO2013036610A2 (fr) 2011-09-07 2013-03-14 University Of Medicine And Dentistry Of New Jersey Compositions comprenant le mg53 et procédés de traitement et de prévention de lésions au niveau des voies respiratoires
KR101413005B1 (ko) * 2007-12-04 2014-07-02 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 세포막 재봉합을 조절하기 위한 조성물 및 방법
US8034770B2 (en) 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
CN101797375B (zh) * 2009-12-02 2013-01-23 北京大学 Mg53蛋白预防和/或治疗心脏缺血/再灌损伤的用途
CN101912617B (zh) * 2010-07-29 2012-09-26 北京大学 Mg53基因在治疗胰岛素抵抗和ⅱ型糖尿病及其相关病症中的应用
US8420338B2 (en) * 2010-11-05 2013-04-16 University Of Medicine And Dentistry Of New Jersey Serum MG53 as a diagnostic marker for tissue injury
US20140024594A1 (en) * 2011-03-31 2014-01-23 Noah Weisleder Compositions and methods for the treatment and prevention of cardiac ischemic injury
WO2012134478A1 (fr) * 2011-03-31 2012-10-04 University Of Medicine And Dentistry Of New Jersey Compositions et méthodes de traitement et de prévention des lésions cardiaques d'origine ischémique
CN103965342B (zh) * 2013-01-25 2015-06-10 北京博雅和瑞科技有限公司 一种mg53突变体及其突变方法和应用
CN103966227B (zh) 2014-03-06 2015-05-27 北京博雅和瑞科技有限公司 密码子优化的mg53蛋白的编码核苷酸序列、其重组体及其应用
CN107266551B (zh) * 2016-04-06 2021-03-05 牡丹江友搏药业有限责任公司 一种mg53突变体及其制备方法和应用
CN107987147B (zh) * 2016-10-26 2024-07-05 牡丹江友搏药业有限责任公司 一种mg53多聚体制备方法及其用途
CN108721601A (zh) 2018-07-26 2018-11-02 海南博芝康医疗科技有限公司 一种预防和/或治疗肾损伤和肾衰竭的组合物
CN109432404A (zh) 2018-12-26 2019-03-08 牡丹江友搏药业有限责任公司 一种含mg53蛋白/mg53突变体蛋白凝胶及其制备方法和应用
CN109528684A (zh) 2018-12-26 2019-03-29 牡丹江友搏药业有限责任公司 一种mg53蛋白/mg53突变体蛋白肠溶胶囊及其制备方法

Also Published As

Publication number Publication date
EP3492491A1 (fr) 2019-06-05
HK1255559A1 (zh) 2019-08-23
WO2018024110A8 (fr) 2018-11-01
US11306296B2 (en) 2022-04-19
CA3031856A1 (fr) 2018-02-08
KR102483242B1 (ko) 2022-12-29
CN108473546A (zh) 2018-08-31
CN108473546B (zh) 2022-08-16
SG11201900459RA (en) 2019-02-27
JP2019530433A (ja) 2019-10-24
TWI781948B (zh) 2022-11-01
WO2018024110A1 (fr) 2018-02-08
JP7144402B2 (ja) 2022-09-29
CA3031856C (fr) 2024-06-25
EP3492491A4 (fr) 2020-02-19
KR20190034278A (ko) 2019-04-01
US20190153406A1 (en) 2019-05-23
TW201805299A (zh) 2018-02-16

Similar Documents

Publication Publication Date Title
MA45797A (fr) Mutant de mg53, son procédé de préparation et ses utilisations
EP3399029A4 (fr) Virus mutant, son procédé de préparation et son application
EP3632907A4 (fr) Dérivé de n-(azaaryl)cyclolactame-1-carboxamide, son procédé de préparation et son utilisation
EP3369848C0 (fr) Suture et son procédé de production
EP3572441A4 (fr) Homopolypropylène et son procédé de préparation
EP3318548A4 (fr) Procédé de production d'hydrochlorofluorooléfine et procédé de production de 2,3,3,3-tétrafluoropropène
EP3998270A4 (fr) Dérivé alcyne, son procédé de préparation et ses utilisations
EP3632903A4 (fr) Composé tenant lieu de modificateur autophage, son procédé de préparation et son application
EP3321259A4 (fr) Nouveau dérivé de la pyrazine, ainsi que son procédé de préparation et son utilisation médicale
EP3556769A4 (fr) Dérivé de polyximine, procédé de préparation et application associés
EP3604367A4 (fr) Copolymère séquencé et procédé de production de copolymère séquencé
PL3142785T3 (pl) Sposób wytwarzania alkenoli i ich zastosowanie do wytwarzania 1,3- butadienu
EP3604470A4 (fr) Composition adhésive et son procédé de préparation
EP3299395A4 (fr) Acide -1,4-oligoglucuronique oxydé, son procédé de préparation et ses utilisations
EP3412679A4 (fr) Magnésium de baïcaline, son procédé de préparation et son application
EP3587375A4 (fr) Composition de béton et son procédé de préparation
EP3653202A4 (fr) Préparation pharmaceutique et son procédé de préparation
EP3425671A4 (fr) Procédé de production de nanotige et nanotige ainsi produite
EP3572404A4 (fr) Hétérocomplexe de butylphthalide-telmisartan, procédé de préparation et application associés
EP3372596A4 (fr) Procédé de préparation de tédizolide, intermédiaire de tédizolide et procédé pour sa préparation
EP3336095A4 (fr) Acide beta-1,4-oligoglucuronique oxydé, son procédé de préparation et ses utilisations
EP3459979A4 (fr) Copolymère de macromonomère et son procédé de production
EP3421518A4 (fr) Copolymère de polyoxalate et son procédé de production
MA54504A (fr) Co-cristal de kétoprofène, compositions le comprenant, son procédé de production et ses utilisations
EP3668928A4 (fr) Copolymère séquencé de polysiloxane-polyester, son procédé de production, et son utilisation